Sovaldi is an antiviral drug owned by Gilead Sciences Inc. It contains the active ingredient sofosbuvir, which is crucial for its effectiveness against the hepatitis C virus (HCV). First authorized for market use on 28 August, 2019, Sovaldi is available in the form of oral pellets.
Sovaldi has a total of 18 patents, protecting it from generic competition. None of these patents have expired yet, meaning Sovaldi is still solely under the control of Gilead Sciences. The last Sovaldi patent is set to expire on 11 June, 2031, after which point generic versions of the drug could potentially be released. An important patent protecting Sovaldi with the title 'Nucleoside phosphoramidates' is set to expire on 2031-06-11.
Sovaldi is used for the treatment of Hepatitis C. Specifically, it targets genotype 1, 2, 3, or 4 chronic Hepatitis C Virus (HCV) infection. Sovaldi's effectiveness comes from its active ingredient sofosbuvir, and is often part of a combination antiviral treatment regimen along with Ribavirin.
Sovaldi holds a number of patents ensuring it stays exclusive to its manufacturer, Gilead Sciences Inc. The most significant patent, titled 'Nucleoside phosphoramidates', expires on 11 June, 2031. At this point, it will be possible for generic versions of Sovaldi to be released. Below are the details of the patents associated with Sovaldi: